Senseonics Holdings, Inc. (SENS)
NYSEAMERICAN: SENS · Real-Time Price · USD
0.460
+0.018 (4.03%)
Dec 20, 2024, 4:00 PM EST - Market closed
Senseonics Holdings Revenue
Senseonics Holdings had revenue of $4.26M in the quarter ending September 30, 2024, a decrease of -30.08%. This brings the company's revenue in the last twelve months to $22.21M, up 11.41% year-over-year. In the year 2023, Senseonics Holdings had annual revenue of $22.39M with 36.62% growth.
Revenue (ttm)
$22.21M
Revenue Growth
+11.41%
P/S Ratio
12.77
Revenue / Employee
$168,220
Employees
132
Market Cap
273.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 22.39M | 6.00M | 36.62% |
| Dec 31, 2022 | 16.39M | 2.71M | 19.85% |
| Dec 31, 2021 | 13.68M | 8.73M | 176.32% |
| Dec 31, 2020 | 4.95M | -16.35M | -76.77% |
| Dec 31, 2019 | 21.30M | 2.39M | 12.63% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TruBridge | 337.67M |
| Lifecore Biomedical | 128.44M |
| AC Immune | 48.51M |
| iTeos Therapeutics | 35.00M |
| Lexicon Pharmaceuticals | 5.23M |
| aTyr Pharma | 235.00K |
| Chimerix | 159.00K |
SENS News
- 6 weeks ago - Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System - GlobeNewsWire
- 2 months ago - Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor - PRNewsWire
- 2 months ago - Eversense 365 Launches in the US: One Year. One CGM. - Business Wire
- 3 months ago - Eversense 365 Receives FDA Clearance: The World's First One Year CGM - Business Wire
- 3 months ago - Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Senseonics Holdings, Inc. (SENS) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Senseonics Holdings, Inc. Reports Second Quarter 2024 Financial Results - Business Wire